Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical ...

The market for drugs that encourage the immune system to attack tumors could explode in the next three years, leading Bristol ...

The deal, which includes $3.5 billion in unconditional payments, underpins BioNTech's ambition to continue a costly long-term ...

Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

Bristol-Myers makes an $11 billion deal with BioNTech to join the new cancer-treatment game, nearly double the size of Pfizer ...

The oncology giant will pay $1.5 billion to co-develop a BioNTech drug that targets the proteins PD-L1 and VEGF, following ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...